Skip to main content

Market Overview

Illumina Shares Lower Amid Action From Multiple Sell-Side Analysts

Share:
Illumina Shares Lower Amid Action From Multiple Sell-Side Analysts

Amid action from multiple sell-side analysts, shares of Illumina, Inc. (NASDAQ: ILMN) are trending downward on the day.

Illumina was recently seen trading down 5.33 percent at $168.10 from a Wednesday close around $177.

Thus far into Thursday's trading, the company's shares reached a high of 173.75 and a low of 167.12.

Deutsche Bank

Deutsche Bank initiated with a Hold with a price target of $192.00 on Wednesday.

"ILMN shares recovered strongly into year-end following steep declines in 2H15 due to overly high expectations, growing fears of increasing competition, and a negative guidance revision," the firm noted.

Related Link: Wells Fargo Downgrades Illumina To Market Perform

Wells Fargo

Wells Fargo downgraded Illumina from Outperform to Market Perform.

The firm noted the following in a research note released Thursday, "The probability that Illumina will announce a product launch big enough to re-accelerate revenue growth in 2016 is low."

AvondalePartners

Avondale initiated coverage of the issue with a Market Perform rating with a $175.00 price target.

The research firm sees Illumina as a dominate player in the next-generation sequencing market, however the firm remains hesitant of its "hefty" valuation. Avondale noted being "skeptical" of Illumina's total market estimate.

Cowen And Company

Cowen and Company raised its price target of the company to $215 on Thursday.

In October, the firm reiterated an outperform rating and issued a $220.00 target price (lowered from $300.00) on shares of Illumina in a research report.

Barclays

Lastly, Barclays raised its target from $170 to $175, maintaining an Equal Weight rating.

Image Credit: Public Domain

Latest Ratings for ILMN

DateFirmActionFromTo
Feb 2022Piper SandlerMaintainsOverweight
Feb 2022SVB LeerinkMaintainsMarket Perform
Jan 2022StifelUpgradesHoldBuy

View More Analyst Ratings for ILMN

View the Latest Analyst Ratings

 

Related Articles (ILMN)

View Comments and Join the Discussion!

Posted-In: Biotech Long Ideas News Downgrades Price Target Initiation Reiteration Analyst Ratings

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com